Outcomes of 50 Cases of Pediatric Liver Transplantation for Intrapulmonary Shunt While Considering the Deteriorated Prognosis of Severe Intrapulmonary Shunt Patients.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 11 02 2019
accepted: 12 03 2019
entrez: 30 9 2019
pubmed: 30 9 2019
medline: 28 12 2019
Statut: ppublish

Résumé

Intrapulmonary shunt (IPS) is recognized in 10% of chronic liver disease patients. Liver transplantation (LT) is associated with a high risk of morbidity and mortality in patients with IPS. Of 519 pediatric LT cases between November 2005 and October 2018, 50 patients with IPS were enrolled in this study. The patients were divided into 3 groups, according to the shunt ratio, calculated by scintigraphy: mild (15%-20%, n = 26), moderate (20%-40%, n = 19), and severe (> 40%, n = 5). We compared the patients' characteristics before LT and the outcomes of LT between these groups. The major original disease resulting in LT in the mild and moderate groups was biliary atresia (73.1% and 52.6%, respectively), while that in the severe group was congenital portosystemic shunt (60%). The median ages at LT were 7.5, 6.1, and 8.3 years in the mild, moderate, and severe groups, respectively. All of the mild and moderate IPS patients lived; however, 3 patients with severe IPS (60.0%) died within 3 months. The shunt ratios of the mild and moderate IPS patients normalized within 2 years after LT, while the 2 surviving severe IPS patients showed a slight improvement. The autopsy findings of the lung in 1 deceased severe IPS patient showed medial hypertrophy and proliferation of intimal cells of the pulmonary arteries, suggesting a diagnosis of portopulmonary hypertension. LT can be safely performed for mild and moderate IPS patients; however, LT for severe IPS patients should be carefully indicated because concomitant portopulmonary hypertension may be masked by IPS.

Sections du résumé

BACKGROUND BACKGROUND
Intrapulmonary shunt (IPS) is recognized in 10% of chronic liver disease patients. Liver transplantation (LT) is associated with a high risk of morbidity and mortality in patients with IPS.
PATIENTS AND METHODS METHODS
Of 519 pediatric LT cases between November 2005 and October 2018, 50 patients with IPS were enrolled in this study. The patients were divided into 3 groups, according to the shunt ratio, calculated by scintigraphy: mild (15%-20%, n = 26), moderate (20%-40%, n = 19), and severe (> 40%, n = 5). We compared the patients' characteristics before LT and the outcomes of LT between these groups.
RESULTS RESULTS
The major original disease resulting in LT in the mild and moderate groups was biliary atresia (73.1% and 52.6%, respectively), while that in the severe group was congenital portosystemic shunt (60%). The median ages at LT were 7.5, 6.1, and 8.3 years in the mild, moderate, and severe groups, respectively. All of the mild and moderate IPS patients lived; however, 3 patients with severe IPS (60.0%) died within 3 months. The shunt ratios of the mild and moderate IPS patients normalized within 2 years after LT, while the 2 surviving severe IPS patients showed a slight improvement. The autopsy findings of the lung in 1 deceased severe IPS patient showed medial hypertrophy and proliferation of intimal cells of the pulmonary arteries, suggesting a diagnosis of portopulmonary hypertension.
CONCLUSIONS CONCLUSIONS
LT can be safely performed for mild and moderate IPS patients; however, LT for severe IPS patients should be carefully indicated because concomitant portopulmonary hypertension may be masked by IPS.

Identifiants

pubmed: 31563247
pii: S0041-1345(19)30123-X
doi: 10.1016/j.transproceed.2019.03.079
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2793-2797

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Yoshihiro Hirata (Y)

Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

Seisuke Sakamoto (S)

Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan. Electronic address: sakamoto-si@ncchd.go.jp.

Shohei Yoshimura (S)

Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

Masahiro Takeda (M)

Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

Hajime Uchida (H)

Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

Seiichi Shimizu (S)

Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

Masayuki Kitamura (M)

Division of Radiology, National Center for Child Health and Development, Tokyo, Japan.

Rie Irie (R)

Division of Pathology, National Center for Child Health and Development, Tokyo, Japan.

Osamu Miyazaki (O)

Division of Radiology, National Center for Child Health and Development, Tokyo, Japan.

Takako Yoshioka (T)

Division of Pathology, National Center for Child Health and Development, Tokyo, Japan.

Syunsuke Nosaka (S)

Division of Radiology, National Center for Child Health and Development, Tokyo, Japan.

Mureo Kasahara (M)

Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH